Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
November 27, 2014, 04:50:11 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 647560
  • Total Topics: 49346
  • Online Today: 205
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 3
Guests: 141
Total: 144

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: CROI 2009: A new strategy to purge latent HIV-1 reservoir  (Read 1437 times)

0 Members and 1 Guest are viewing this topic.

Offline John2038

  • Member
  • Posts: 1,529
  • Happiness is a journey, not a destination.
    • HIV Research News (Twitter)
CROI 2009: A new strategy to purge latent HIV-1 reservoir
« on: February 25, 2009, 05:34:20 AM »

Gisslen and colleagues (abstr. 88) presented provocative findings suggesting the IV immunoglobulin therapy could reduce the frequency of latent HIV-1 infection. Like many great ideas in medicine, this trial was sparked by a clinical observation: a patient on ART was treated with IV Ig for an autoimmune disease, stopped ART, and remained aviremic for several months. The idea was that the mild immune and complement activation induced by IV Ig might ignite replication of latent HIV, and its clearance.
 
9 subjects on ART were treated with 30 gm IV Ig for 5 days. Highly purified resting memory CD4+ T cells were isolated and activated, and replication-competent HIV-1 was quantified. Replication-competent HIV-1 was detected in resting T cells in 7 of the 9 subjects. IVIG was said to decrease the frequency of resting CD4 cell infection by more than 68% during the study period (8 to 12 weeks) in 5 of 9 subjects. The investigators also observed a transitory increase in plasma HIV-1 RNA using a sensitive assay (LOD 2 copies/ml), and in increase in serum IL-7 levels.
 
This study was provocative and interesting, especially given the safety record of IV Ig. However, the frequency of resting cell infection appeared to vary over a range of 50 to 0.1 per million in the patients studied, and the quantitative measurements of infection could not be explained by the presenter. It was not clear how many replicate cultures were studied, and what quantitative change in viral recovery led to the conclusion that resting cell infection had decreased three-fold. These findings would need to be clarified, but if shown to be credible the further testing and validation of this pilot study might be worthwhile.

Here is the abstract:

Background:  The latency of HIV-1 in resting CD4+ T lymphocytes constitutes a major obstacle for the eradication of the virus in patients on ART. As yet, no approach to reduce this viral reservoir has proven effective.

Methods:  We treated 9 subjects on effective ART with high-dose intravenous immunoglobulin (IVIG) for 5 consecutive days. Highly purified resting memory CD4+ T cells were isolated and activated. Cells containing replication-competent HIV-1 were quantified. We also quantified HIV-1 RNA in plasma by an ultrasensitive test with detection limit of 2 copies/mL. HIV-1 from plasma and activated memory CD4+ T cells were compared with single genome sequencing (SGS) of the gag region. T lymphocyte activation markers and serum interleukins were measured.

Results:  Replication-competent HIV-1 was detected in resting T cells in 7 of the 9 subjects. IVIG had a profound effect on the latent HIV-1 pool which decreased by more than 68% during the study period (8 to 12 weeks) in 5 subjects when added to an effective ART. The decrease was preceded by a transitory low-level increase in plasma HIV-1 RNA and serum interleukin 7 (IL-7) levels, and followed by an expansion of T regulatory cells. The magnitude of the viral increase in plasma correlated to the size of the latent HIV-1 pool. SGS of the gag region showed that viral clones from plasma clustered together with virus from activated memory T cells.

ConclusionsOur findings indicate that the latent HIV-1 reservoir became accessible by IVIG through activation of HIV-1 gene expression in latently-infected resting CD4+ T cells, possibly mediated by IL-7.

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.